Your 25-second video preview has ended.

to continue watching, please Log In or Register:

Log in / Register

Taking the Long VIEW in AMD

  Channels: Retina | Posted 11/29/2016

Since the completion of two parallel phase 3 randomized, double-masked, multicenter clinical trials, VIEW 1 and VIEW 2, long-term outcomes of aflibercept (Eylea, Regeneron) have been assessed in further clinical trials. In this installment of the AMD Resource Center, W. Lloyd Clark, MD, summarizes some of the results of an extension study that included patients from the VIEW 1 trial, which accumulated data out to 4 years of follow-up, and the 1-year interim results of a further 2-year treat-and-extend follow-up study called RANGE

AMD • AMD Disease Education Resource Center • Clinical Trials • Wet AMD

Related Videos